UNSPSC 51385606: Guacetisal

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6EKB9V2O2, chemically known as benzoic acid, 2-(acetyloxy)-, 2-methoxyphenyl ester but generally known as guacetisal, which bears US NIH Compound Identifier 68749. European Medicines Agency schedules Guacetisal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07968MIG. The term GUACETISAL is an International Non-Proprietary Name.

UNSPSC 51385606 Guacetisal is a Commodity code that appears in state and local procurement records with minimal direct relevance to its nominal classification. The recent opportunities tagged under this code reflect pharmaceutical procurement—naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals—rather than the specific product category the code nominally identifies. State and local governments use this code designation inconsistently; the mismatch between the code name and the actual work being solicited suggests either a data-entry error in how opportunities are tagged or a broader categorization issue within individual jurisdictions' systems.

The three recent opportunities span Florida county health procurement, a Texas state health agency's exploratory market research, and a multi-state cooperative purchasing alliance for pharmaceutical distribution. Seminole County, Florida (IFB 60459723LAS, response deadline July 26, 2023) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building; the Texas Health and Human Services Commission (RFI HHS0017013, April 3, 2026) gathered vendor capability data on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) established multi-state contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers. Activity appears concentrated in the Southeast and Midwest, with multi-state cooperative vehicles gaining traction. Given the loose correlation between the code designation and actual pharmaceutical procurement solicitations in the record, vendors should verify coding accuracy with individual issuing bodies before committing resources to opportunities tagged under this code.